Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Conditions

Nasopharyngeal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Jun Ma, M.D.) · majun2@mail.sysu.edu.cn · +86-20-87343469
Contact: Principal Investigator (Jun Ma, M.D.)

Study leads

Jun Ma, MD
Principal Investigator
Sun Yet-senU

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma · High-Risk Cancer · Maintenance Therapy

Abroad (travel likely)RecruitingPHASE3

Ganzhou, China · Guangzhou, China

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Fuzhou, China · Xiamen, China

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE2

Singapore, Singapore · Singapore, Singapore

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma · Sintilimab

Abroad (travel likely)Recruiting

Nanning, China